EGFR Mutant Subset Analysis From Archer 1009: a Randomized Double Blind Phase 3 Efficacy and Safety Study of Dacomitinib Versus Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | Publicación